Celltrion has started supplying the first South Korean-made COVID-19 monoclonal antibody treatment Rekirona to healthcare institutes from Feb. 17.

Rekirona is a first COVID-19 antibody treatment developed and manufactured in South Korea and it was approved by the Ministry of Food and Drug Safety (MFDS) with condition to further submit clinical data.

The company stated it completed manufacturing doses for 100,000 people to treat patients in the country, and it plans to annually manufacture doses for 1.5 million to 3 million people, depending on the demand.

MFDS indicated the drug to treat patients confirmed to have COVID-19, within seven days of the diagnosis, who are age